The Stop-Loss Crisis: Why Your Safety Net May Have a $4 Million Hole

49% of plan sponsors reported claims exceeding $1 million last year — double the rate from the year before. And stop-loss carriers are responding not by covering you better, but by finding creative ways to limit their exposure to the most expensive treatments.

In this episode, I break down:

→ Why stop-loss insurance was built for a different era (when catastrophic meant $300K, not $4.25 million)

→ What carriers are actually doing — lasering, exclusions, and reimbursement term misalignment — to push risk back to employers

→ The gene therapy pipeline problem: 48 approved therapies today, dozens more coming, and no historical data to predict frequency

→ Why even jumbo employers who've never needed stop-loss should reconsider

→ The 5 things every self-funded employer needs to do at renewal — including the one question that will tell you everything about your coverage

The mainstream story is that gene therapy is a miracle of modern medicine. It is. But the financial infrastructure wasn't built for this reality, and carriers have decided that the most expensive thing in healthcare is now predictable enough to exclude.

You should find that arrangement concerning.

📺 Watch the full video breakdown:
https://youtu.be/1wwrtwmYAPE

📖 Read the Substack post with sources:
https://open.substack.com/pub/danmccoymd/p/the-stop-loss-crisis-what-self-funded

📧 Subscribe for more healthcare benefits analysis:
https://danmccoymd.substack.com

Transcript

SPEAKER_00 0:00

Here's something that should concern every employer in America who self-funds their own health plan. You've been told by your broker, your consultant, your carrier that stop loss insurance is your safety net. The thing that protects you when an employee gets hit with a catastrophic claim. We're talking cancer, a transplant, a premature baby in the NICU for six months. We've all heard it. That was true, and for about 40 years it worked. But last year, 49% of plan sponsors reported claims exceeding $1 million, double the rate from the year before. And the insurance carriers responded by doing something remarkably creative. They started finding ways to limit their exposure to the most expensive new treatments through the very product designed to cover them. The real story isn't the $4 million drugs, it's what's happening to the insurance behind them. To understand why this matters, you need to understand what stop loss was actually built for. When self funding took off in the late 70s and early 80s, employers needed protection against the occasional catastrophic claim. Not every claim, just the big ones. A bad car accident, a complicated cancer case, maybe once or twice a year someone would hit $300,000 or a half million dollars. Stop loss insurance handled this beautifully. You set an attachment point, say $250,000 per individual, and anything above that, the carrier picks up. It was simple, predictable, and for decades the math worked for everyone. Then gene therapy happened. So Ginsmo was approved in 2019 at $2.25 million for spinal muscular atrophy. That was shocking at the time. It really shouldn't have been. It was just the beginning. Today there are multiple FD-approved therapies with list prices above $2 million. The most expensive, LA Meldi, for a rare neurological condition, carries a list price of $4.25 million for one patient and one treatment. And here's the part that should keep benefit managers up at night. 48 cell and gene therapies have been approved to date, according to EBRI. The pipeline remains active with additional approvals expected over the next several years. And in February, the FDA issued draft guidance on a plausible mechanism framework for individualized therapies targeting ultra-rare genetic conditions. And this is going to accelerate approvals even faster. Stop loss was built for a world where a million dollar claim was an outlier. We now live in a world where a single drug can cost four times that. Now, the conventional wisdom here among benefits consultants goes something like this. Gene therapies are expensive, yes, but they're incredibly rare. Fewer than one-tenth of 1% of your employees will ever need one. The probability of a gene therapy claim hitting your plan at any given year is vanishingly small. Your stop loss has you covered, so don't panic. And the data supports this, at least on the surface. QBE North America, a major reinsurer, reported only three gene therapy claims across nearly 2 million covered lives between 2022 and 2024. Three claims. 2 million people, three years. That's a probability so low it barely registers on an actuary spreadsheet. So the rational move, if you listen to your consultant, is to just keep your existing stop loss, maybe bump the attachment point a little bit to control premiums, and trust the odds are in your favor. Sounds reasonable, but here's what that analysis misses. It assumes the stop loss you're paying for actually covers gene therapy claims. And increasingly, guess what? It doesn't. Let's look at what the carriers are actually doing. Stop loss premiums have been rising 8% to 14% annually since 2022. Claim frequency is up 37%. Claims exceeding $3 million rose 47% year over year. Voy a stop loss analysis reported individual claims are well into the millions. So premiums are up, frequency is up, severity is up, you'd think this means the carriers are investing more heavily in covering catastrophic events. You would be delightfully naive. The key concern, and benefits consultants like Locton, have been raising this alarm is what carriers can do through a practice called lasering. If they identify someone in your plan who might be a gene therapy candidate, say an employee's child with sickle cell disease, they can raise the individual's attachment point from, say, $1 million to $2 million and maybe even higher. The practical effect is the same. The risk stays with you, the premium stays with them. And it doesn't stop there. Stop loss policies can also limit coverage through medical necessity definitions, condition-specific exclusions, or reinsurance terms that don't align with your plan document. If you don't scrutinize the fine print on your renewal, you may discover the gap at the worst possible moment when you're staring at that $3 million claim and calling your carrier for reimbursement. Locton, one of the largest benefit consultancies in the world, has warned employers to ensure medical necessity definitions and exclusions don't conflict with coverage intentions and to verify reinsure agreement on gene therapy treatment as a covered expense. Let me translate that for you. Your carrier may be looking for reasons to deny your largest claims, and your plan document ambiguity may be their best friend. So let me make sure I understand this correctly. Premiums are rising double digits, claim frequency is up 37%, and the tools available to carriers, lasering, exclusions, title reimbursement terms, it gives them every incentive to limit their exposure to the most expensive new treatments. That's a remarkable position to be in if you're the carrier. Now there are counterarguments worth considering, and some of them are legitimate. The first, gene therapy claims are still extremely rare. Three claims for two million lives, the expected value calculation still favors maybe taking the risk. Fair point. But it ignores the pipeline. 48 therapies are approved today, and the development pipeline is deep. Dozens more are in late-stage trials across multiple therapeutic areas. Sickle cell disease alone affects 100,000 Americans, and there are now two approved gene therapies for it priced between $2.2 and $3.1 million. The FDA's new draft guidance on individualized therapies could accelerate approvals for conditions we haven't even been able to treat before and probably you've never heard of before. The calm you're experiencing right now, that's the last few years before this pipeline hits. Summit Ree's own claims data shows 19 Solgins of patients cost $41 million in drug costs between 2019 and 2024. Only 11% of those were self-funded commercial members. Most were Medicaid. But as these therapies multiply and Medicaid eligibility tightens, the commercial exposure will grow dramatically. The second counterargument, Carve Out program, saw this. This one actually has some merit. EverNorth, that's Cygnus Pharmacy Arm offers something called Embark Benefit Protection. It started in 2019 covering two therapies. Today it covers more than 10, with more added as they're being approved. The cost is roughly $1 to $4 per employee per month. As of January this year, it's portable across medical carriers. You don't need to be on Cygna anymore. CVS Care Mark has a similar product that's backed by Aetna, including installment payment options to spread cost over multiple years. BCS Financial offers dedicated gene therapy reinsurance pools. These products exist, they work, and most employers have actually never heard of them. The third counterargument: outcomes-based contracting sounds wonderful in conference rooms. Locked in put it plainly, and I'm quoting them directly. We have yet to see an employer actually implement one. The operational barriers, we're talking tracking outcomes across providers and payers and manufacturers for years after treatment, that's prohibitive. And kind of add that to the list of things that work in PowerPoint, but really not in practice. Now here's a hidden angle most people miss. Stop loss carriers, whatever their other faults, tend to audit claims more aggressively than your typical third-party administrator. They scrutinize medical necessity, they check plan document alignment, they pursue subrogation and coordination of benefits. And for a $3 million gene therapy claim, that level of scrutiny has real value. Payment integrity, which we're talking catching fraud, waste, and overbuilding, is an underappreciated benefit of having a stop loss carrier in the picture. Even if they're making your life harder on exclusions, they may be saving you money on the claims that they actually do cover. And that brings up a bigger question, one that challenges decades of conventional wisdom and benefit strategy. There's a whole category of employers. We're talking the mega jumbos, the 10,000 plus life plans who have never purchased stop loss. And the logic has always been sound. If you have a 50,000 employee life plan, a million dollar claim is a rounding error. You can absorb the volatility. So why pay a carrier premium to cover the risk when you can manage it yourself? The math has always favored self-retention for the largest employers. But we're now entering a world where that math, well, it may no longer hold. So let's think about it. A $4 million claim is manageable. But what happens when you have five gene therapy claims in the same plan year? 10. With 100,000 sickle cell patients in America, two approved therapies above $2 million, and 60 more drugs in the pipeline? This isn't a single lightning strike anymore. It's a weather problem. A 50,000 life plan could realistically see three to five gene therapy claims in a year by 2030. At $3 million each, that's $9,000 to $15 million in unexpected spend. For a plan that budgets $8,000 to $10,000 per member per year, that's still less than 1% of total spend. It's manageable. But the variance is what kills you. One bad year with eight claims, that's $24 million your CFO didn't forecast. And here's what makes it different from cancer or transplants. The actuaries don't have good data on gene therapy utilization rates yet. Cancer incidence, it's well modeled. Transplant rates are predictable, but gene therapies for diseases that were previously untreatable? There's no historical claims data to build a model on. You're flying blind on frequency, and the per unit cost is four times anything the system was built for. So maybe the question isn't why would a jumbo plan buy stop loss? Maybe the question is, what kind of stop loss makes sense for a plan that's never needed it before? Not traditional stop loss with all those exclusion games, but something with guardrails, a gene therapy-specific layer, a captive arrangement with reinsurance above a high threshold. A consortium model where large employers pull gene therapy risk across hundreds of thousands of lives. The point is the employers who have always been big enough to go naked on stop loss may need to rethink that posture. Not because a single claim will break them, but because the pipeline of multi-million dollar treatments is about to make tail risk, a lot less tail, and a lot more risk. If you're an employer renewing your health plan this year, here's what you need to do. First, read your stop loss policy, not the summary, the actual policy. Look for gene therapy exclusions, condition-specific carve outs, and lasering provisions. If your broker can't walk you through these in detail, that tells you something. Second, evaluate dedicated gene therapy coverage programs. EverNorth Embark, CVS CareMark Gene Therapy Stop Loss, BCS Financial. Budget roughly $4 per employee per month for dedicated coverage. That's the current market rate according to Dano. For a 500-person company, that's about $24,000 a year to protect against a $3 million claim. That's not insurance, that's kind of arithmetic. Third, understand your exposure profile. If you're a mid-size employer, 200 to 5,000 employees, you're the most vulnerable. 90% of plans your size carry stop loss, but you have the least negotiating leverage with carriers. A single gene therapy claim can represent a double-digit share of your annual health spending. Fourth, and this is new territory, if you're a jumbo employer who's never carried stop loss, it's probably time to model the gene therapy tail. Not a traditional stop loss, but a dedicated gene therapy layer or captive arrangement. The cost of being wrong on frequency estimation is no longer a couple of million dollars. It's potentially tens of millions of dollars in a single plan year, and there's no historical data to really predict it. Fifth, and this is the question I'd want answered at renewal, regardless of the size of your plan. Ask your broker, if an employee needs a $3 million gene therapy next year, what exactly happens? Walk me through the entire claim pathway. Who pays what, where the exclusions are, what the attachment point looks like after lasering. If they can't answer that precisely, well, that's your answer. The mainstream story about gene therapy is that it's a miracle of modern medicine. And honestly, as a physician, it is. A child with spinal muscular atrophy who would have died can now be treated with a single infusion. A person with sickle cell disease who spent their entire life in and out of hospitals can be functionally cured. These are genuine medical breakthroughs. The science is extraordinary. But the financial infrastructure designed to absorb their costs, the stop loss market that self-funded employers actually depend upon, is under structural pressure. It really wasn't built for. Carriers are raising premiums and the tools at their disposal, we're talking lasering, exclusions, title reimbursement terms. They create a widening gap between what employers think they're covered for and what they're actually covered for. With a deep pipeline of gene therapies and development and the FDA expanding pathways for approval, employers who don't scrutinize or coverage now will discover the gap at the worst possible moment. When someone's child needs a $4 million treatment and the fine print says, well, it's not covered. Stop loss insurance was designed to protect you from the unpredictable. The carers have decided that the most expensive thing in healthcare now is predictable enough to actually exclude. You should find that arrangement, well, concerning. If you like this content, please like and subscribe to my Substack or check me out on YouTube, and I'll keep creating this content. And until next time, I'll see you then.